The USA FDA has revoked the emergency use authorization for four COVID-19 antibody drugs.

On December 24, Gelonghui reported that the USA Food and Drug Administration (FDA) has revoked the emergency use authorization for four COVID-19 antibody drugs, including Eli Lilly and Co's bebtelovimab, AstraZeneca's Evusheld, GlaxoSmithKline's sotrovimab, and Regeneron's REGEN-COV. The FDA stated in a letter earlier this month that the shelf life of these drugs has expired, and due to the spread of non-susceptible variants, they have not been authorized for patient use for more than a year. According to the FDA, the four companies mentioned above do not intend to continue providing the relevant products in the USA and will notify customers and suppliers.

Gelonghui FinanceDec 24 14:58

Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know

Yahoo Finance06:45

Eli Lilly's Weight Loss Med Tirzepatide Gets Endorsement From U.K.'s NICE

Seeking Alpha00:35

With EPS Growth And More, Eli Lilly (NYSE:LLY) Makes An Interesting Case

Yahoo FinanceDec 24 20:00

Eli Lilly's Anti-Obesity Drug Mounjaro to Be Supported by UK Public Health System for Some Patients

MT NewswiresDec 24 19:07

U.S. stocks closed higher | The three major Indexes collectively rose, with the Nasdaq increasing by nearly 1%; chip stocks surged, with Broadcom and Taiwan Semiconductor rising over 5%, and NVIDIA increasing nearly 4%.

① The Nasdaq China Golden Dragon Index rose by 0.91%; ② The PHLX Semiconductor Index rose by over 3%; ③ MicroStrategy purchased 5,262 Bitcoins; ④ The suspect in the UnitedHealth executive's murder case pleaded not guilty.

cls.cnDec 24 07:07